Amplitude-integrated EEG in Improvement of Seizure Detection and Prognostication in Children With TBI (aEEG)
Can Bedside Amplitude-integrated EEG Improve Seizure Detection and Prognostication in Children With Traumatic Brain Injury in a Hospital With Limited Access to Conventional EEG?
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Ilona Shemyakina, BSc
- Phone Number: 4053 514-345-4931
- Email: ilona.shemyakina@recherche-ste-justine.qc.ca
Study Locations
-
-
Quebec
-
Montréal, Quebec, Canada, H3T 1C5
- Recruiting
- CHU Sainte-Justine
-
Contact:
- Ilona Shemyakina, BSc
- Phone Number: 4053 15143454931
- Email: ilona.shemyakina@recherche-ste-justine.qc.ca
-
Principal Investigator:
- Geneviève Du Pont-Thibodeau, MD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- moderate to severe TBI defined by a post-resuscitation Glasgow Coma Scale (GCS) of 3-8 (severe) or 9-12 (moderate), this includes those with accidental TBI, abusive head trauma, and cases of polytrauma
- decision by the primary medical team to initiate cEEG monitoring
Exclusion Criteria:
- patients for whom it is impossible to record cEEG for any reason will be excluded from the study
- premature neonates
- brain death or suspected brain death at PICU entry
- unavailable equipment for cEGG and/or aEEG
- consent to participate denied by parents and/or patient
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Children with moderate to severe TBI
|
Amplitude-integrated EEG (aEEG) is a compressed form of real-time conventional EEG monitoring that will be added to cEEG monitoring.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
accuracy of PICU physicians at detecting seizures when using aEEG in real-life clinical setting during the continuous EEG monitoring of patients with moderate to severe TBI
Time Frame: 18 months
|
PICU physicians should correctly detect > 70% of all subclinical seizures.
False positives rates should be < 20%.
|
18 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Determine whether a 2-hour aEEG teaching session is sufficient for PICU physicians to achieve similar seizure detection rates as experts in aEEG interpretation.
Time Frame: 18 months
|
After a 2 hour aEEG training session, PICU physicians should have similar sensitivity and false positive rates as experts in aEEG.
|
18 months
|
|
Determine whether aEEG background activity correlates with patients' neurological outcome.
Time Frame: 18 months
|
Continuous and reactive backgrounds should correlate with a good neurological outcome.
Low voltage, discontinuous or burst suppression backgrounds should correlate with a poor neurological outcome.
|
18 months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Geneviève Du Pont-Thibodeau, MD, MSc, Sainte-Justine University Hospital Research Centre
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CHUSJ 2018-1556
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.